drugset / Trial / NCT01263496
Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the long-term safety and efficacy of SYR-322, once daily (QD), to an α-glucosidase inhibitor, three times daily (TID), administered for 40 consecutive weeks in participants who completed a phase 2 dose-ranging study.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 6.25 mg | Oral |
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Alogliptin | Unknown | 25 mg | Oral |
| Subject | Alogliptin | Unknown | 50 mg | Oral |
| Comparator | Voglibose | Small molecule | 0.2 mg | Oral |